Lucentis, used to treat age-related macular degeneration and diabetic macular edema, costs more than $2,000 per dose. Avastin, which works similarly, costs about $40 per dose. But Avastin has not been approved for this use by the Food and Drug Administration.
“These are big dollars that could be saved for Medicare and patients,” David Hutton, the lead author of the study, told Bloomberg Business News. Hutton is an assistant professor of health management and policy at the University of Michigan in Ann Arbor.
Read the full story: